surpass-cvot tirzepatide trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized SURPASS CVOT

But the standard dose ranges are completely different

Thats because Fubstahas higher efficacy and better adherence to the plan

Real-world results depend on clinical eligibility, dosing, adherence, tolerability, lifestyle factors, and provider guidance

However, it is important to know about possible side effects

The possibility of confounding by indication should also be considered, as patients prescribed GLP-1RAs may have more severe metabolic disease or different risk profiles than those managed with other approaches

Explore our medically-supervised tirzepatide protocol to ensure you're getting the clinical support and monitoring that maximizes your results